RAB29 and Parkinson disease: Our data also suggest that inhibitors targeting the LRRK2 ankyrin domain would be expected to block Rab29 binding and inhibit activity of LRRK2 in cells, thereby offering therapeutic potential for the treatment of Parkinson's disease.